Retrospective analysis of hepatitis C infected patients treated through an integrated care model

Table 1 Direct-acting antivirals classifications[7,8]

Class (targeting non-structural proteins)	Examples
NS3/4A protease inhibitors
First generation	telaprevir, boceprevir
Second generation	grazoprevir1, paritaprevir2, simeprevir
NS5A inhibitors	ledipasvir1, ombitasvir2, daclatasvir, elbasvir1
NS5B RNA-dependent RNA polymerase inhibitors
NS5B nucleoside polymerase inhibitors	sofosbuvir
NS5B non-nucleoside polymerase inhibitors	dasabuvir1

¹Only available as fixed dose combinations;

²Available in 2 fixed dose combinations.

Table 2 Baseline demographics n (%)

Total patients	133 (100)
Median Age	58
Male	89 (66.9)
Cirrhosis	47 (35.3)
Treatment Experienced	33 (24.8)

Table 3 Adverse events

Adverse events > 5%	n (%)
Fatigue	58 (41.4)
Headache	38 (28.6)
Nausea	24 (18.1)
Diarrhea	11 (8.3)
Dyspepsia	7 (5.3)
Anemia	7 (5.3)